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Abstract
Background: Subjective pain assessment scales have been widely used for assessing lameness in response to pain,
but the accuracy of these scales has been questioned. To assess scale accuracy, 10 lame, presa Canario dogs with
osteoarthritis (OA) associated with bilateral hip dysplasia were first treated with mesenchymal stem cells. Then,
potential lameness improvement was analyzed using two pain scales (Bioarth and visual analog scale). These
data were compared with similar data collected using a force platform with the same animals during a period of
6 months after treatment.
Results: The F test for intraclass correlation showed that concordance in pain/lameness scores between the 2
measuring methodologies was not significant (P value≥ 0.9213; 95 % confidence interval, –0.56, 0.11). Although
subjective pain assessment showed improvement after 6 months, force platform data demonstrated those same
animals had returned to the initial lameness state.
Conclusion: Use of pain assessment scales to measure lameness associated with OA did not have great accuracy and
concordance when compared with quantitative force platform gait analysis.
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Background
Intensity of pain is difficult to accurately assess in dogs.
Veterinarians assess the severity of pain in their patients
using scoring systems based on several signs, including
patient vocalization, activity level, degree of lameness,
and reaction to manipulation. However, all of these signs
are subjective and may be influenced by a variety of
external factors [1].
Historically, 3 categories of subjective pain scoring
systems have been used in veterinary medicine to as-
sess pain severity and enable investigators to compare
different therapeutic strategies: behavioral response
(e.g., vocalization), physiologic indices (e.g., heart
rate), and visual reports. Some of the most commonly
used subjective scoring systems to assess pain include
visual analog scales (VAS), numeric rating scales
(NRS) and simple descriptive scales, all of which are
based on behavioral signs [2]. Investigators have also
attempted various combinations of these categories in
an effort to devise a more complete pain scoring
method (e.g., University of Melbourne Pain Scale) [3].
The usefulness of physiologic variables (heart rate, re-
spiratory rate, blood pressure, pupil dilation, and serum
epinephrine, norepinephrine, b-endorphin, and cortisol
levels) to measure pain is limited because they measure
not only the patients’ level of pain, but also their level of
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stress, fear and sedation, and can be affected by certain
health conditions [4–7]. In addition, recent studies have
shown that physiologic variables have no correlation
with VAS reports or combination pain scores. To date,
no single, readily acquired physiologic measurement has
been consistently established as the standard for pain
severity detection in cats or dogs [8–10].
In dogs, lameness scores depend upon visual observa-
tion of gait. Using a VAS, limb function is determined by
marking points on a line scale, with 1 end of the line
representing clinical normality (soundness) and the
other end representing maximum lameness (i.e., non-
weight bearing). On the other hand, NRS can also quan-
tify certain characteristics (signs) that can define pain
and/or lameness. These characteristics are classified in 4
−5 descriptive categories as crepitation on mobilization,
degree of muscle atrophy, functional limitation, range of
movement, etc., [11].
Specifically, VAS is a unidimensional, subjective scale
based on the level of pain intensity shown by the patient.
It has been widely used for the assessment of sensorial in-
tensity, experimentally-induced pain, and the mechanisms
and efficacy of pharmacologic and non-pharmacologic
treatments [12, 13].
The Bioarth scale is based on an NRS system and con-
sists of 2 parts: 1 that scores radiological evidence of
osteoarthritis (OA), and a second part that evaluates
joint functionality by scoring functional limitation,
articular mobility, and muscular atrophy [14].
Regardless of the scale methodology used in the field
of veterinary medicine, the main disadvantage of scale
systems is that the person who performs the evaluation
of pain is the owner and/or the veterinarian. This intro-
duces a variable, i.e. the observer, which can significantly
alter pain scores [15] [see Additional file 1].
Based on these premises, some degree of variability
exists in subjective assessments performed by an indi-
vidual or group. This fact makes the interpretation of
NRS or VAS results a challenge for investigators and
clinicians [16].
Kinetic gait analysis has become an accepted tech-
nique for accurate and objective evaluation of limb func-
tion in humans and animals [17, 18]; for that reason,
force platform gait analysis can be used as a tool to de-
termine pain, disease, and healing of different units of
the locomotor system [19–21]. In the same manner, this
device is consistently used as an accurate, objective
method to document the efficacy of different medical
treatments of OA in dogs [22–25].
With a force platform, limb function is commonly an-
alyzed measuring the peak vertical force (PVF, maximal
force applied during stance phase) and vertical impulse
(VI, total force applied over time) to quantitatively assess
the degree of lameness [26–28].
In the field of regenerative veterinary medicine, au-
tologous mesenchymal stem cell (MSC) therapy is a rap-
idly growing area of research. Stem cells have been
shown to have an affinity for damaged joint tissue. In
addition, recent in vivo studies have confirmed that stem
cells have the ability to participate in the repair of
damaged joint structures, including cruciate ligaments,
menisci, and cartilage lesions [29]. However, several
studies in MSC treatment of dogs with hip OA have re-
ported different outcomes regarding duration of effect
[14, 30, 31]. In those investigations, study designs varied,
and animals of different conformations were examined.
The objective of this study was to evaluate the con-
cordance between subjective and objective measures of
limb function in dogs of the same breed that had OA
lameness due to bilateral hip dysplasia and were treated
with autologous MSCs. It was hypothesized that results
obtained using the Bioarth and VAS scales, on the 1




Ten adult, client-owned presa Canario dogs (6 males, 4
females) with lameness and pain attributed to OA asso-
ciated with hip dysplasia were included in the study. A
control group consisted of 5 sound and healthy dogs of
the same breed. The sample size was selected based on
the availability of the subjects of the same breed, same
pathology and similar degree of severity in order to
achieve a study group with maximal homogeneity. None
of the dogs were forced to perform physical activity.
Ventrodorsal radiographs of the hips were performed
under sedation with intravenous (i.v.) dexmedetomidine
0.05 mg (dexdomitor, Esteve, Barcelona, Spain) and anal-
gesia with intramuscular (i.m.) butorphanol 0.05 mg/kg
(torbugesic, Pfizer, Madrid, Spain). The obtained images
confirmed the presence of OA compatible with D and E
degrees of hip dysplasia as defined by the Fédération
Cynologique Internationale (World Canine Organization).
All D-degree dysplastic dogs showed obvious deviation
from the norm with evidence of a shallow acetabu-
lum, flattened femoral head, poor joint congruency,
and in some cases, subluxation with marked changes
of the femoral head and neck. All E-degree dysplastic
dogs showed complete dislocation of the hip and se-
vere flattening of the acetabulum and femoral head
(Fig. 1a and b) [32].
Additional radiographs of knee and elbow joints and
the lumbosacral region were taken after physical, ortho-
pedic, and neurologic examinations were performed to
ensure that hip OA was the main reason for the ob-
served clinical signs in the study group and that general
health was otherwise normal.
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Extraction and culture of MSCs
Stem cell extraction was performed under premedication
with a combination of i.m. buprenorphine 0.01 mg/kg
(Buprex, RB Pharmaceuticals, Bogotá, Colombia) and
acepromazine 0.05 mg/kg i.m. (Equipromacina, Faltro
ibérica, Barcelona, Spain). General anesthesia was induced
with i.v. propofol 3 mg/kg (Vetofol, Esteve, Barcelona,
Spain) and maintained with sevoflurane (SevoFlo, Abbott,
Madrid, Spain). Patients were positioned in decubitus
supinus. A biopsy of 20 g subcutaneous fat tissue (4–
5 cm3) was collected from the inguinal region through a
small surgical incision, and 120 mL blood was isolated
under aseptic conditions and processed with the Dog
Stem kit according to the manufacturer’s instructions. The
incision was sutured with a simple, interrupted pattern.
Meloxicam 0.1 mg/kg q 24 h PO (Metacam, Boehringer
Ingelheim, Barcelona, Spain) was administered for 3 days
post-surgery. Immediately after sample collection, fat bi-
opsy and blood (in an anti-coagulant container) were
maintained at 4 °C and sent for cell isolation and amplifi-
cation under current GMP conditions to the Fat-Stem
Laboratory (Belgium). The fat was processed with collage-
nase, and the cells were concentrated by centrifugation;
the cells were then cultured in a bioreactor with con-
trolled temperature and O2 and CO2 concentrations.
Quality control was ensured by evaluating cell markers,
sterility tests, and viability counts. Two weeks after biopsy,
the Fat-Stem Laboratory returned the cultivated cells in
two 2-mL, certified tubes containing 15 million adipose
MSCs per tube.
Inoculation of MSCs
The adult MSCs were infiltrated aseptically into the hip
joints of the study dogs through conventional arthro-
centesis sites. For this phase, the dogs were sedated with
the same protocol used to take the radiographs. Prior to
inoculation, fur was clipped in the articular region for
both groups (study and control) in order to preserve the
blindness of the study. The needle was introduced just
cranioproximal to the trochanter major, aimed slightly
ventrally and caudally. The appearance of joint fluid
confirmed proper needle placement [33]. Once the ex-
cessive synovial liquid was drained, the MSCs were
injected. Owners were advised to use meloxicam for pain
management at home, if needed.
Force platform gait analysis
Gait analysis was performed using a single platform
mounted in the center of, and level with, a 7-m runway
covered by a rubber mat. The mat weight was discarded
by setting the tare button to “0 force” after the platform
was covered. Dogs were leash guided at walk over the
force platform by the same handler. Walk velocity was
measured by use of a motion sensor (PS-2103a, Pasco,
CA, USA) positioned 1 m from the platform. This device
allowed the handler to ensure that animals walked
homogeneously within a narrow variation of velocity
(1.6 ± 0.5 m/s) and acceleration (≤ ± 0.5 m/s2).
Five valid trials, at a sampling frequency of 250 Hz, were
obtained for each dog by an investigator blinded to the
study (JMV). A trial was considered valid when the limb
fully contacted the force platform at the approximate cen-
ter, with the dog walking next to the handler without pull-
ing on the leash. The trial was discarded if the dog
appeared distracted during the measurement, if the limb
struck the edge of the force plate, or if any portion of the
contralateral paw hit the force plate. The platform was
interfaced with a dedicated computer using DataStudio
(Pasco, CA, USA), software specifically designed for the
acquisition, numerical conversion, and storage of data.
Both affected limbs were recorded at day 0, 30, 90, and
180 post-treatment. Finally, the obtained PVF and VI
values were normalized relative to body weight (%).
Although each dog had bilateral lameness, only the
measurements obtained from the more lame limbs
(lesser PVF) were considered reliable, in order to avoid a
possible bias caused by inconsistent weight redistribution
to the less affected contra-lateral hindlimb. Only data
from the more lame limbs were statistically compared
using the Bioarth and VAS scales. The subjective methods
Fig. 1 Radiographs showing lesions corresponding with D-degree (a) and E-degree (b) hip dysplasia
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used did not discriminate between limbs, and potential
gait anomalies evaluated by the observer were recorded
for the limb whereby lameness was more evident.
Subjective scales
VAS
VAS was graphed using a horizontal line, 100 mm in
length, anchored by word descriptors at each end: “NO
PAIN” on the left and “WITHOUT SUPPORT” on the
right. An experienced clinician blinded to treatment group
(JMC) marked on the line the points at which himself and
the client/owner felt represented the current lameness
state of the dog. The VAS score was then determined by
measuring in millimeters from the left end of the line to
the mean value given by clinician and dog owner scores.
The obtained results were expressed in percentages. A
higher value means more severe lameness.
Bioarth assessment scale
Functional assessment using the Bioarth assessment
scale evaluates the 3 basic functional parameters: func-
tional limitation, joint mobility, and muscle atrophy. For
functional limitation, dog owners in the study group
responded to a series of questions regarding weight
bearing of the affected limbs; changes in posture (antal-
gic postures); characteristics of lameness; reluctance to
move, play, or jump; and reluctance to climb stairs. The
scale ranges from 0 to 23 points.
Joint mobility was measured by examining the limita-
tions of joint movement via the range of motion of the hip
joint. Maximal extension and flexion were determined
using a goniometer centered on the hip center of rotation
(scale 0 − 7 points). This procedure was performed on dogs
from both groups by a different blinded observer (BC).
Atrophy degree was categorized as no atrophy (0 points),
mild atrophy (1 point), or severe atrophy (2 points). This
was performed on all dogs by the same observer. The sum
of all 3 functional parameters (functional limitation, articu-
lar mobility, and muscle atrophy) categorized the arthrosis
degree. A higher score indicates more severe lameness
(Additional file 1).
Both VAS and Bioarth scales tests were performed
at the same time as the force platform analysis test
was performed.
Statistical analysis
Parameters in this model were estimated by using the linear
and nonlinear mixed effects (nlme) models package in R stat-
istical software [34]. Data were analyzed by a different,
blinded researcher who did not perform acquisition of data
(AS).
A linear mixed effects model for a blocked design with
repeated measures was considered. The experimental
factor (time) and the status (lame–sound) of the dog
were considered as fixed effects factors, while the block-
ing factor (dog) was a random effects factor. Because the
dogs represent a random sample of the population of
interest, any interaction terms modeling differences be-
tween dogs in its response when changing from different
observation periods were also expressed as random
effects.
Significance of the differences in PVF and VI between
periods of observation were tested by means of analysis
of variance of these models. Following this analysis,
post-hoc comparisons between fixed effects were per-
formed using Tukey’s procedure. For assessing the valid-
ity of the model, the Shapiro-Wilk test was applied for
testing normality of the residuals. Significance level was
set at P ≤ 0.05 in all tests.
Concordance coefficients were calculated with the F test
of intraclass correlation [35] to assess the accuracy of the
observer versus PVF and VI data. The irr R package was
used to compute the intraclass correlation values and its
significance [36]. A concordance of 1 was considered a
perfect agreement, whereas a concordance of 0 referred to
no agreement.
Results
The body weight of enrolled dogs ranged from 46 to
65.2 kg (mean ± SD: 51.21 ± 5.48 kg), and ages were 4 −
9 years (mean: 5.6 ± 2.3 years). Walking velocity of both
sound (control) and diseased groups of dogs was 1.6 ±
0.5 m/s. No significant difference in walking velocity was
observed between dogs (P = 0.08).
Force platform analysis
Mean values for PVF and VI are summarized in Table 1.
Table 1 Mean and standard deviation of peak vertical force (PVF)
and vertical impulse (VI) in more-lame and less-lame limbs
Parameter Day
0 30 90 180
PVF
ML 39.69 ± 3.43a 46.73 ± 4.56b 41.61 ± 4.3 39.00 ± 3.82
LL 48.15 ± 6.16 49.74 ± 6.79 50.53 ± 4.7 48.13 ± 6.29
S 44.96 ± 3.67 45.91 ± 3.53 45.90 ± 3.65 45.84 ± 3.68
VI
ML 12.16 ± 1.1a 14.12 ± 1.45b 12.58 ± 1.33 11.88 ± 1.27
LL 14.61 ± 1.9a 15.06 ± 2.07b 15.38 ± 1.55 14.66 ± 2.06
S 13.66 ± 1.28 14.04 ± 1.33 13.99 ± 1.20 14.03 ± 1.28
Results are shown in % body weight (N/N and N.s/N, respectively) for each day
of observation. Different superscript letters within rows indicate significant
differences (P < 0.05)
ML more-lame limbs, LL less-lame limbs, S sound limbs from control group
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Analysis of PVF
A significant effect of time on PVF (P = 0.001) was de-
tected: at day 30, more-lame limbs improved signifi-
cantly (P = 0.0001) by 7.04 % of body weight (BW) from
day 0 (Table 1). On the other hand, for days 90 and 180,
there were no significant differences (P = 0.1573 and
P = 0.6073, respectively) with respect to day 0.
Compared with the control group, the day 0 lame
group supported 5.28 % less BW (P = 0.0228). At day
30, there were no significant differences between groups
(P = 0.6948). At day 90, the difference was still not signifi-
cant (P = 0.0558), but at day 180, the difference (6.84 %
less BW) was again significant (P = 0.0052) (Fig. 2).
Analysis of VI
Compared to day 0, at day 30 there were significant differ-
ences in VI (P < 0.0001), but at days 90 and 180, the differ-
ences were not significant (P = 0.3037 and P = 0.4851,
respectively) (Table 1). Compared with the control group,
at day 0 the lame group had significant differences in VI
(P = 0.0323). At day 30, there were no significant differ-
ences between groups (P = 0.9298); however, at day 90, the
difference was already significant (P = 0.0437), and at day
180, the difference was again significant (P = 0.0042)
(Fig. 3). The Shapiro-Wilk test showed normality of resid-
uals (P = 0.6043).
Subjective analysis
Bioarth and VAS scores are summarized in Table 2.
When these results were graphically observed, scores
resulting from use of both scales showed progressive
improvement in lameness during the study period
(Figs. 4 and 5).
Concordance analysis
Concordance values are shown in Table 3. There was a
lack of concordance among objective and subjective
recordings.
Discussion
Pain is an emotional response to a painful stimulus and
is difficult to reliably determine in a nonverbal animal.
Pain of the locomotor system can usually be detected by
a certain disability to support weight; in other words,
lameness is the expression of pain.
For clinicians, the outset of a therapeutic strategy for
lameness associated with pain should be based on ob-
jective results of efficacy. This is of vital importance in
order to choose the most convenient therapeutic option
and to determine when a new cycle of treatment should
be applied to stop a relapse [37].
In this study, the effect of MSCs on lameness in dogs
affected by hip OA was investigated using subjective and
objective methods. In addition, the resultant data were
compared between these methods in order to determine
the accuracy level of subjective methods in the evalu-
ation of lameness in dogs.
The study was designed using a control group of
sound dogs. Sound dogs were chosen as the control be-
cause, as has been previously reported, when a treated
group improves its lameness, a lame, non-treated control
Fig. 2 Evolution of peak vertical force (PVF) in lame-group dogs after treatment with mesenchymal stem cells at days 30, 90, and 180. The control
group is also shown for reference
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group could worsen [38], making these animals unable
to provide fixed reference data.
Patient velocity has been shown to have a significant
effect on force platform values and should be limited to
a narrow range when data are obtained [39]; therefore,
the design for the current study included dogs of the
same breed to ensure comparable conformations and a
narrow range of velocities. In addition, a previous study
[40] indicated that the use of multiple handlers can be
an insignificant contributor of variability in a dog’s gait
when narrow limits of velocity are maintained. Although
the authors agree, they preferred to use the same hand-
ler for all dogs and in all testing periods in order to
reach maximal uniformity.
The role of VI in measuring the evolution of lameness is
controversial. While some authors suggest that recordings
of improvement in VI may suffer from a delay, other au-
thors affirm that stance time did not change or increase
when limb function improved [28, 41]. In fact, the current
study observed a slight difference in the evolution of both
PVF and VI values; compared with sound dogs,
differences in VI were already detected at day 90, while
PVF did not show a return to initial state until day 180. In
our opinion this happens because PVF depends only on
the maximal force exerted by the limbs, while VI reflects
the evolution of the force during the whole support phase.
For this reason, VI could vary when one or both variables
change (force and support time). Nevertheless, concord-
ance between PVF and VI was almost 1.
Both VAS and Bioarth have been previously validated
for use in assessing lameness and pain in dogs [15].
However, it has been found that these methods lack valid-
ity when performed by individuals untrained in recogniz-
ing clinical signs of pain [42]. Surprisingly, although the
first part of Bioarth scoring was performed by dog owners
and VAS by an experienced clinician, when these 2 scales
were compared, a high concordance level was found.
When subjective and objective data were compared,
concordance coefficients were calculated to assess the
accuracy of the observer in the detection of variations of
lameness in treated animals with respect to PVF and VI
recorded from the same dogs at the same checking pe-
riods. Concordance was chosen over correlation because
correlation coefficients explain how closely the variables
are linearly related; however, the line they match may
not have a slope of 1. Correlation disregards how close
the actual data is, and instead shows how closely they fit
a trend or best-fit line. Concordance coefficients explain
how 2 variables are related to a line with a slope of 1.
Therefore, concordance assesses how close the variables
are to each other rather than the best-fit line and, in
Table 2 Mean and standard deviation of Bioarth and (VAS) scores




0 30 90 180
Bioarth 22.3 ± 4.27 14.7 ± 5.56 11.8 ± 4.92 10.6 ± 5.27
VAS 54.77 ± 8.79 33.08 ± 9.89 20.8 ± 9.13 15.2 ± 9.03
Data are shown for each day of observation
Fig. 3 Evolution of vertical impulse (VI) in lame-group dogs after treatment with mesenchymal stem cells at days 30, 90, and 180 follow-up. The
control group is also shown for reference
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agreement with other authors, constitutes a better meas-
ure of accuracy [16, 43].
Based on the results, a great discordance was found
when subjective and objective methods were compared.
In fact, Bioarth and VAS scores showed good results for
MSC therapy after 6 months of inoculation, in agree-
ment with previously published data [31] (although this
study had a different design and was performed with
dogs of different conformations and weights). In con-
trast, force platform parameters demonstrated how ani-
mals had almost returned to their initial state; this
discordance, in the opinion of the authors, can likely be
explained by the presence of a placebo effect that af-
fected not only the owners, but also the blind observer.
With respect to the dogs’ conformation, a molossoid
breed was chosen for various reasons. Firstly, this breed
shows a high incidence of hip dysplasia. Secondly, the high
BW makes gait analysis easier to perform. And thirdly,
this particular breed can act as an animal model poten-
tially useful to extrapolate results to human medicine,
mainly because the behavior of these animals when they
are lame is similar to humans due to their heavy BW.
Small and some medium dogs raise their limbs (especially
pelvic limbs) to avoid pain, even when the pain is mild or
moderate, making it difficult to quantify the effectiveness
of a treatment. Large-breed dogs, as in humans, continue
to support their lame limb/s on the ground, redistributing
the weight to the contralateral limb in an effort to alleviate
pain, proportionally to pain degree.
In the authors’ opinion, accurate calculation of pain
(lameness) by observing certain postures, behaviors,
and/or subjective appreciations is difficult, even though
the observer may be an experimented clinician. In con-
trast, force platform analysis is more objective and quan-
tifiable for the detection and quantification of lameness.
This statement is strengthened by a previous report [1],
Fig. 4 Evolution of lameness in dogs using the Bioarth scoring scale at days 0, 30, 90, and 180 post-treatment with mesenchymal stem cells. The
control group is also shown for comparison
Fig. 5 Evolution of lameness in dogs using the visual analog scoring (VAS) scale at days 0, 30, 90, and 180 post-treatment with mesenchymal
stem cells. The control group is also shown for comparison
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concluding that nearly 10 times more (331 versus 38)
dogs would have been needed per group to ascertain
statistical significance between groups when a subjective,
observed gait analysis score is used for comparison. In
addition, other studies [11, 44] have previously reported
poor correlation between subjective and objective
methods for measuring limb function. In these studies, it
was stated that a variable collected objectively and gen-
erated by the patient is superior to a variable collected
subjectively and generated by an observer. For statistical
interpretation, objective variables lend themselves to
more powerful statistical approaches.
However, this does not necessarily mean that kinetic
analysis of limb function is the only reliable indicator of
the severity of pain. Objective data can also be obtained
with kinematic [45] and inverse dynamics [46], avoiding
the observer and inter-observer variations that are en-
countered with pain scoring systems.
As suggested by a recent study, the authors agree that
a 6-month follow-up period can be considered a stand-
ard for testing the evolution of medical or surgical treat-
ments [47]. In the current study, 6 months was also
enough to detect great differences among different strat-
egies to test lameness in dogs. In fact, the dogs in the
current study seemed to improve during the first month
after treatment, but this effect had disappeared within a
period inferior to 6 months, although this change was
detectable only by force platform.
In general, force platform analysis shows some limita-
tions. First of all, much time and effort is required to obtain
valid recordings. Secondly, the analysis must be performed
with dogs of a relatively high body weight. Finally, these de-
vices are relatively expensive. These considerations limit
their use as ordinary diagnostic tools. On the other hand,
the great shortcoming of VAS and NRS in assessing object-
ive data from lame dogs, also supported by this study, may
indicate that new subjective scoring scales should be ex-
plored if kinetic or kinematic devices for lameness detec-
tion are not available. In this line of thought, more recent
studies have showed that new, validated scoring
questionnaires can be reliable and give repeatable results
even when used by inexperienced observers [48, 49]. Al-
though these new tools were not used in this study, they
should be explored in future studies.
Conclusion
MSC therapy significantly improved limb function in dogs
with hip OA, but the duration of the improvement was in-
ferior to 6 months post treatment. Subjective evaluation
of gait correlates poorly to objective measures of limb
function. For this reason, subjective evaluation of gait
should be interpreted cautiously as an outcome measure.
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